7 results about "Endogenous metabolism" patented technology

This invention generally relates to a technique for degrading systemic toxins in vivo by enhancing the metabolic function of the lungs. Such a technique involves introducing a composition into the lung tissue of a subject, the composition comprising at least one enzyme known to enzymatically break down at least one toxin systemically present in the subject's body. The provided technique enables the lungs to act as a modulated metabolic organ, thereby promoting the removal of toxins from the systemic circulation of a subject, such as a subject suffering from a condition leading to the accumulation of toxins or endogenous metabolites, or a subject who has ingested toxic substances.

The application discloses application of cell endogenous metabolites in preparation of medicines for treating and / or preventing aging. The cell endogenous metabolites are any one or combination of phosphocreatine, hypotaurine and / or phosphoethanolamine. The application finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively restore cell growth, reduce cell SA-beta-Gal staining intensity, improve cell mitochondrial function and increase ATP yield, restore cell mitochondrial membrane potential, alleviate damage caused by cell oxidative stress and premature aging, and also prolong the life of nematodes and restore exercise capacity in the middle of aging. Meanwhile, the three metabolites have a synergistic effect, and by adjusting the matching concentration of the three metabolites, the same cell protection effect can be achieved by mixed administration. Since the endogenous metabolites are accurate, efficient and safe, the three cell endogenous metabolites provided by the application can be used for preparing anti-aging medicines.

The invention relates to the technical field of biological detection, in particular to a sequencing analysis method for urine metabolites of uranium contaminated rats and application of the sequencing analysis method. The analysis method comprises the following steps: S1, animal grouping and uranium exposure; s2, collecting and treating a urine sample; s3, chromatography-mass spectrometry detection: analyzing the treated sample by adopting an ultra-high performance liquid chromatography-tandem mass spectrometry method to obtain mass spectrometry data of the metabolite; and S4, data analysis: carrying out pretreatment, peak extraction and identification on the mass spectrum data to obtain quantitative information of metabolites, and screening differential metabolites between the control group and the uranium exposure group by utilizing multivariate statistical analysis. According to the invention, an HM700 metabonomics method is adopted to research obviously changed endogenous metabolites and related metabolic pathways in a urine sample after uranium exposure, and a potential target spot is provided for evaluating and treating uranium-caused kidney injury.

The invention discloses a preparation method of alpha-ketoisovaleric acid in an anti-hepatic fibrosis drug, and relates to the technical field of hepatic fibrosis treatment drug development, and the preparation method comprises the following steps: mixing alpha-ketoisovaleric acid with pharmaceutic adjuvants to prepare a pharmaceutically acceptable dosage form; the dosage of the alpha-ketoisovaleric acid is determined based on the pharmacological activity of the alpha-ketoisovaleric acid in the concentration range of 50 mu M to 200 mu M, wherein the alpha-ketoisovaleric acid can inhibit hepatic stellate cell activation induced by a transforming growth factor-beta; an endogenous metabolite alpha-ketoisovaleric acid is applied to preparation of an anti-hepatic fibrosis medicine, and based on the pharmacological activity of the alpha-ketoisovaleric acid for specifically inhibiting activation of TGF-beta induced hepatic stellate cells at the concentration of 50-200 mu M, a novel anti-hepatic fibrosis preparation which is high in safety, wide in therapeutic window and free of liver and kidney accumulation risk is developed. The medicine is not only suitable for treating hepatic fibrosis caused by various causes such as non-alcoholic fatty liver disease, viral hepatitis, alcoholic liver disease and drug-induced liver injury, but also meets the requirements of early intervention and severe treatment through reasonable dosage form design and administration route selection.

The invention discloses an application of an endogenous metabolite micromolecule GGOH in preparation of liver cancer drugs, the structural formula of GGOH is as shown in formula (I): GGOH can be spontaneously converted into GGPP after entering the liver, and the GGOH can specifically up-regulate gluconeogenesis in the liver and reduce glycolysis level, so that the glucose metabolism steady state of the liver is improved, and the occurrence and development of fatty liver diseases are inhibited. The invention discloses the application of the endogenous metabolite micromolecule GGOH in preparing the fatty liver disease medicine or treating the liver cancer for the first time, clarifies the key regulation effect of the GGOH / GGPP level in the occurrence and development of the fatty liver disease, opens up a new direction for treating the fatty liver disease related to metabolic disorder, and has important scientific significance and clinical application prospects.

The application discloses a method for extracting and purifying endogenous metabolites after exposure of zebra fish to patulin, which comprises the following steps: weighing a sample to be detected and adding acetonitrile-water mixed extraction liquid, oscillating and centrifuging to obtain extraction liquid and residues, taking out the extraction liquid, repeatedly extracting the residues, combining the extraction liquid, adding ammonium acetate, oscillating and centrifuging to obtain upper acetonitrile phase and lower water phase, taking the water phase layer to pass through a diatomite column, balancing, using pure acetonitrile as an eluent to perform elution, obtaining eluent, adding the acetonitrile phase to neutral alumina powder, oscillating and then low-temperature standing, then low-temperature high-speed centrifuging to obtain supernatant, combining the obtained eluent and the obtained supernatant, nitrogen blowing to near dryness, using a methanol-water mixed solution to constant volume, then high-speed centrifuging, and finally being ready for analysis. The application has high detection efficiency, can determine important biomarkers generated after exposure of zebra fish to patulin, and can provide a detection basis for poisoning monitoring of the compounds.

The invention discloses discovery of an anti-heart-failure traditional Chinese medicine monomer composition based on a Zhenwu decoction. The discovery comprises the following steps: 1, preparing the Zhenwu decoction; 2, collecting and analyzing a serum sample; 3, determination of heart failure resistant endogenous metabolites and determination of peak intensity; 4, determination of components absorbed into blood and determination of peak intensity; 5, carrying out correlation analysis on peak intensity; the traditional Chinese medicine monomer composition is obtained by dissolving songlin, atractylenolide II, pachymic acid, paeoniflorin and 6-gingerol in a sodium carboxymethyl cellulose solution, and plays a role in preparing the heart failure resisting medicine. According to the method disclosed by the invention, the heart-failure-resistant endogenous metabolite and absorbed blood-entering component information of the true Wu decoction are simultaneously obtained through one-time liquid chromatography-mass spectrometry analysis, so that the heart-failure-resistant active component of the true Wu decoction is further obtained, the time is saved, and the result accuracy is improved; the traditional Chinese medicine monomer composition disclosed by the invention is stable and controllable in quality, has an effective heart failure resisting effect and is suitable for preparing heart failure resisting medicines.